Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

in

blood Phe level of 236 uM/L (29 percent) compared to a mean increase

of 3 uM/L (3 percent) in the placebo group (p<0.0001). Prior to

treatment, patients in the Kuvan group and placebo group had mean

blood Phe levels of 843 uM/L and 888 uM/L, respectively.

* After six weeks of treatment, 54 percent of patients treated with

Kuvan and 23 percent of patients in the placebo group had a blood

phenylalanine concentration below the recommended 600 uM/L level

(p=0.003).

* Blood phenylalanine concentrations fell by about 200 uM/L after one

week in the Kuvan group, and this reduction persisted for the

remaining five weeks of the study (p<0.0001).

* The type and incidence of adverse events was similar in the Kuvan

and placebo groups. Kuvan was well tolerated and investigators

reported that no serious adverse event occurred.

About Kuvan

Kuvan is an investigational oral small molecule therapeutic for the treatment of PKU. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. Clinical data suggest that treatment with Kuvan results in significant reductions in blood Phe levels in BH4-responsive patients. It also may enable some patients to minimize or eliminate highly-restrictive dietary constraints by increasing Phe tolerance levels. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). If approved, it will receive seven years of market exclusi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 SynCardia Systems, Inc., has been recognized ... Small Companies presented by the Arizona Technology Council in ... 11th annual Governor,s Celebration of Innovation Awards honor technology ... Arizona Governor Jan Brewer ... was honored for its Freedom® portable driver, which powers ...
(Date:11/18/2014)... , Nov. 17, 2014  Nopras Technologies ... Stewart B. Rosenberg to the position ... Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a ... consultancy he founded 27 years ago, focused in ... care.  With undergraduate and graduate degrees in biology, ...
(Date:11/18/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ("Zimmer") announced ... (the "EC") to extend the deadline for the EC,s ... limited number of days in order to provide the ... extensions are not uncommon in such in-depth investigations.  Zimmer ... facilitate their review of the pending transaction and is ...
Breaking Medicine Technology:SynCardia Named Innovator of the Year by the 2014 Governor's Celebration of Innovation Awards for Its Freedom Portable Driver 2SynCardia Named Innovator of the Year by the 2014 Governor's Celebration of Innovation Awards for Its Freedom Portable Driver 3Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 2Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 2Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 4Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 5
(Date:11/18/2014)... AZ (PRWEB) November 18, 2014 ... in medical information, risk management and investigative services, ... Star Examiner Performance Model to enhance its paramedical ... distribution partners. Through use of EMSI’s 5 ... in knowing that their paramedical exams are conducted ...
(Date:11/18/2014)... By Dennis Thompson ... (HealthDay News) -- Driving "bad" LDL cholesterol down to ... significantly reduce heart attacks and strokes in high-risk patients ... experienced fewer heart attacks and strokes when taking Vytorin, ... with a non-statin medication called ezetimibe, said principal investigator ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Routine screening for heart disease ... symptoms but are at high risk for a heart ... the screenings do not help prevent heart attacks or ... unstable angina (chest pain that occurs when the heart ... is still the best way to manage risks for ...
(Date:11/18/2014)... BellasDress has announced the launch of 85 new models of ... fabrics, the new styles of prom dresses have attracted many ... gifts in a variety of colors and styles. , “We ... are created by top designers,” said the vice president for ... our sales team and more than one client has told ...
(Date:11/18/2014)... 18, 2014 OpenWorks, one of America’s ... the 2014 Lincoln Guild Invitational. The John C. Lincoln ... support the Phoenix-area Desert Mission community programs. Open Works ... The tournament was held at Camelback Golf Club in ... the efforts of Desert Mission — including a food ...
Breaking Medicine News(10 mins):Health News:EMSI Launches Proprietary 5 Star Examiner Performance Model to Enhance Paramedical Exam Service 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 3Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2Health News:OpenWorks Sponsors 2014 Lincoln Guild Invitational Golf Tournament Hosted by Scottsdale's Camelback Golf Club 2
... , MONDAY, March 26 (HealthDay News) -- ... preserve their fertility while undergoing cancer treatment, a new ... with cancer need more information about fertility preservation methods ... Rosen, of the University of California, San Francisco, and ...
... --Teen girls are twice as likely as boys to use ... who analyzed in-car video clips of American teen drivers, behavior. ... driving behavior for both genders, but there were a number ... by the AAA Foundation for Traffic Safety. The video ...
... Results of a study presented at the Society of ... Calif., signal a light at the end of the ... (LAPC). A new procedure called irreversible electroporation or IRE ... tumor cells around a vast and delicate network of ...
... Physicians (ACP), representing 132,000 internal medicine specialists and medical student ... (ACA) has resulted in major improvements in access and coverage ... physicians. Considering that it is just a little over two ... of its programs are not yet fully effective, the ACA ...
... Brazil, Russia, India, China and South Africa are injecting ... in the world,s poorest countries, according to a report released ... many traditional donors reduce or slow their spending, the report ... and development. While all five countries have been ...
... intervention (PCI), also known as coronary angioplasty or angioplasty, ... PCI involves opening a blocked blood vessel by threading ... a stent is also inserted to keep the blood ... usually give patients medicine to prevent complications that may ...
Cached Medicine News:Health News:Few Young Women With Cancer Take Steps to Preserve Fertility 2Health News:Teen Girl Drivers Likelier to Use Electronic Devices: Study 2Health News:Electrical pulse treatment gives pancreatic cancer patients new hope 2Health News:The present and future of the Affordable Care Act 2Health News:The present and future of the Affordable Care Act 3Health News:The present and future of the Affordable Care Act 4Health News:BRICS bringing new resources and approaches to health and development as other donors lag 2Health News:BRICS bringing new resources and approaches to health and development as other donors lag 3Health News:Complications in patients undergoing PCI tend to occur within first 30 days 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: